Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction

Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction

To evaluate the circulating levels of remodeling biomarkers procollagen type 1 C-terminal propeptide (PICP), human cartilage glycoprotein-39 (YKL-40), plasma renin activity (PRA), aldosterone (Aldo) as well as clinical and echocardiographic parameters in patients with heart failure with reduced ejec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC cardiovascular disorders 2022-05, Vol.22 (1), p.217-217, Article 217
Hauptverfasser: Bolla, Giovanni Battista, Fedele, Antonella, Faggiano, Andrea, Sala, Carla, Santangelo, Gloria, Carugo, Stefano
Format: Artikel
Sprache:eng
Schlagworte:
Aldosterone
Aminobutyrates - adverse effects
Analysis
Angiotensin Receptor Antagonists - therapeutic use
Biological markers
Biomarkers
Biphenyl Compounds - therapeutic use
Blood pressure
Cardiac output
Cardiovascular disease
Care and treatment
Cartilage
Chitinase-3-Like Protein 1
Collagen
Congestive heart failure
Creatinine
Diagnosis
Dosage and administration
Drug dosages
Ejection fraction
Fibrosis
Health aspects
Heart failure
Heart Failure - complications
Heart Failure - diagnosis
Heart Failure - drug therapy
Hemodynamics
Humans
Inflammation
Inflammation - complications
Left ventricular ejection fraction
Measurement
Mortality
Patients
Peptides
Prevention
Procollagen
Renin
Risk factors
Sacubitril/Valsartan
Stroke Volume
Tetrazoles - pharmacology
Tetrazoles - therapeutic use
Valsartan
Valsartan - therapeutic use
Variance analysis
Ventricle
Ventricular Dysfunction, Left - complications
Ventricular Function, Left
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To evaluate the circulating levels of remodeling biomarkers procollagen type 1 C-terminal propeptide (PICP), human cartilage glycoprotein-39 (YKL-40), plasma renin activity (PRA), aldosterone (Aldo) as well as clinical and echocardiographic parameters in patients with heart failure with reduced ejection fraction (HFrEF), before and after treatment with Sacubitril/Valsartan (S/V). A total of 26 consecutive patients with HFrEF on stable clinical conditions were studied. Clinical, echocardiographic parameters and circulating biomarkers were measured at baseline, after 30 and 60 days of S/V treatment. Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) decreased, from 126 ± 15 to 113 ± 4 mmHg (p 
ISSN:1471-2261
1471-2261
DOI:10.1186/s12872-022-02647-0